Omeros (OMER) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Omeros

NasdaqGM•Healthcare•Biotechnology

$18.95-0.16(-0.01%)Market closed

Market Cap

$1.33B

P/E

10.7x

P/S

34.6x

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

How this company scores

WeakMetricSide Score: 37/100

Grade capped at D — Negative equity — the balance sheet is insolvent. Strongest: Growth (14/25); weakest: Balance Sheet & Red Flags (5/25).

Profitability9/25

Growth14/25

Balance Sheet & Red Flags5/25

Cash & Earnings Quality9/25

Strengths

Rising earningsProfit converts from growthImproving margins

Grade capped at D

Negative equity — the balance sheet is insolvent.
Interest coverage below 1× (0.0x) — earnings cannot cover interest.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 10.7x5y range 0.9x – 10.7x

Currently above its 10-quarter median.

P/S · 34.6x5y range 5.2x – 71.3x

Currently above its 6-quarter median.

P/B · 16.3x5y range 1.7x – 17.5x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 7 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $1.33B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $38.42M
Q. Revenue: $28.53M
TTM EBITDA: $-71.91M
TTM Op. Income: $-72.82M
Q. Op. Income: $74,000
TTM Net Income: $124.83M
Q. Net Income: $13.23M
EPS: $0.18
Shares Out.: $72.13M

$38.42M in TTM revenue grew from zero YoY, reaching $28.53M last quarter. TTM EBITDA of $-71.91M and TTM operating income of $-72.82M show growth is flowing through to the bottom line. TTM net income of $124.83M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 2 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: 0.9%
Op. Margin: 0.3%
Net Margin: 46.4%

Op. margin of 0.3% is up 3235400000.3% YoY — cost efficiency is improving. Net margin at 46.4% Across the last 8 quarters, operating margin has risen for 2 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 10.7x
P/S Ratio: 34.6x
P/B Ratio: N/A

At 10.7x P/E, the stock trades below typical market levels. P/S of 34.6x and P/B of 0.0x provide additional context. P/E sits below typical market levels while revenue is growing. Over the past year, P/E is up 0% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $286.83M
Cash: $1.99M
Long-Term Debt: $42.03M
Book Value: $-51.35M
D/E Ratio: N/A
Debt/EBITDA: 157.4

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $4.15M
TTM Free Cash Flow: $-68.73M
FCF Margin: -178.9%
FCF / Net Income: -0.6

TTM FCF of $-68.73M on $4.15M in operating cash flow. The FCF / Net Income ratio of -0.6x means the business consumes cash — it is not yet self-funding. Across the last 8 quarters, free cash flow has risen for 2 consecutive quarters — an improving trend.